CLEAN VERSION OF EACH REPLACEMENT PARAGRAPH/SECTION/CLAIM AND

INSTRUCTIONS FOR ENTRY

IN THE SPECIFICATION:

As a result of these procedures, the disease specific markers (M12529) apolioprotein E having a molecular weight of about 1033.5431 and having a sequence identified as SEQ ID NO: 1, (J02908) apolipoprotein J precursor having a molecular weight of about 1393.6963 and a sequence identified as SEQ ID NO: 2, (M10065) apolipoprotein E having a molecular weight of about 1497.8025 daltons and a sequence identified as SEQ ID NO: 3, Chain A, Apolipoprotein E (Apoe3) Truncation Mutant 165 having a molecular weight of about 1753.8972 daltons and a sequence identified as SEQ ID NO: 4, (J02908) apolipoprotein J precursor having a molecular weight of about 1873.9911 daltons and a sequence identified as SEQ ID NO: 5, apolipoprotein A-IV precursor having a molecular weight of about 1927.9514 daltons and a sequence identified as SEQ ID NO: 6, and (J02908) apolipoprotein J precursor having a molecular weight of about 1999.9666 daltons having a sequence identified as SEQ ID NO: 7 related to Alzheimers disease were found.

IN THE CLAIMS:

1. A biopolymer marker selected from the group having a sequence identified as SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or at least one analyte thereof useful in indicating at least one particular disease state.

18. A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues